Tacrolimus therapeutic drug monitoring in Tunisian renal transplant recipients: Effect of post-transplantation period

被引:9
作者
Ben Fredj, N. [1 ]
Chaabane, A. [1 ]
Chadly, Z. [1 ]
Hammouda, M. [2 ]
Aloui, S. [2 ]
Boughattas, N. A. [1 ]
Skhiri, H. [2 ]
Aouam, K. [1 ]
机构
[1] Fac Med, Serv Pharmacol, Monastir, Tunisia
[2] EPS Monastir, Serv Nephrol, Tunis, Tunisia
关键词
Therapeutic drug monitoring; Tacrolimus; Kidney transplantation; Post-transplantation time; PHARMACOKINETICS; CYP3A4; POLYMORPHISMS; REQUIREMENTS; CYCLOSPORINE;
D O I
10.1016/j.trim.2013.04.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Most previous studies having focused on therapeutic drug monitoring of tacrolimus in renal transplant recipients have assessed the clinical response of patients. The aim of this study is to investigate the influence of post-transplant delay on tacrolimus dose, trough levels (CO) and dose/CO ratio in a Tunisian renal transplant population. Patients and methods: A retrospective study including 110 renal transplant patients has been performed. Tacrolimus trough concentrations were adjusted according to the target range proposed by the European consensus conference on tacrolimus optimization. Samples for determination of tacrolimus blood level were subdivided according to the post-transplantation period into three groups. Results: The initial dose required was 0.17 +/- 0.05 mg/kg/day during the first 3 months after transplantation. A reduction of 36 and 65% of tacrolimus initial dose during the second (3-12 months) and third period after transplantation (>12 months), respectively, was required to maintain the concentration level within therapeutic range. These results were different from those found in other studies performed in different populations. We hypothesize that these differences in dosing requirement may be due to an interethnic polymorphism in the expression of enzymes involved in tacrolimus metabolism. Conclusion: These results could provide a simple therapeutic strategy to optimize tacrolimus prescription after renal transplantation in Tunisian,population. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:198 / 202
页数:5
相关论文
共 20 条
  • [1] Racial variation in dosage requirements of tacrolimus
    Andrews, PA
    Sen, M
    Chang, RWS
    [J]. LANCET, 1996, 348 (9039) : 1446 - 1446
  • [2] Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients
    Antignac, Marie
    Barrou, Benoit
    Farinotti, Robert
    Lechat, Philippe
    Urien, Saik
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (06) : 750 - 757
  • [3] Therapeutic drug monitoring of tacrolimus in kidney transplantation: 9-month follow-up
    Brunet, M
    Torregrosa, JV
    Oppenheimer, F
    Corbella, J
    [J]. TRANSPLANTATION PROCEEDINGS, 1998, 30 (08) : 4068 - 4069
  • [4] Cheng YL, 2005, HONG KONG J NEPHROL, V7, P57
  • [5] de Jonge H, 2011, PHARMACOGENOMICS, V12, P1281, DOI [10.2217/PGS.11.77, 10.2217/pgs.11.77]
  • [6] A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
    Elens, Laure
    Bouamar, Rachida
    Hesselink, Dennis A.
    Haufroid, Vincent
    van der Heiden, Ilse P.
    van Gelder, Teun
    van Schaik, Ron H. N.
    [J]. CLINICAL CHEMISTRY, 2011, 57 (11) : 1574 - 1583
  • [7] Demographic considerations in tacrolimus pharmacokinetics
    Fitzsimmons, WE
    Bekersky, I
    Dressler, D
    Raye, K
    Hodosh, E
    Mekki, Q
    [J]. TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) : 1359 - 1364
  • [8] Hedayat S, 1996, J Biopharm Stat, V6, P411, DOI 10.1080/10543409608835153
  • [9] Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
    Hesselink, DA
    van Schaik, RHN
    van der Heiden, IP
    van der Werf, M
    Gregoor, PJHS
    Lindemans, J
    Weimar, W
    van Gelder, T
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (03) : 245 - 254
  • [10] Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients
    Hu, RH
    Lee, PH
    Tsai, MK
    [J]. TRANSPLANTATION PROCEEDINGS, 2000, 32 (07) : 1689 - 1692